Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Immucell Corp changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 27 | 31 | +4 |
| Shares | 1.37M | 1.33M | −35.9K (−2.6%) |
| Value | $8.67M | $13.4M | +$4.73M (+54.6%) |
New holders (7)
Institutions that held Immucell Corp at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 15,751 | $158.3K | 0.00% |
| Quadrature Capital Ltd | 15,415 | $154.9K | 0.00% |
| Mercer Global Advisors Inc | 12,000 | $120.6K | 0.00% |
| FMR LLC | 160 | $1.61K | 0.00% |
| Tower Research Capital LLC (TRC) | 32 | $322 | 0.00% |
| Barclays PLC | 30 | $302 | 0.00% |
| Caitong International Asset Management Co., Ltd | 5 | $50 | 0.00% |
Sold out (3)
Institutions that held Immucell Corp at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Essex Financial Services, Inc. | 11,000 | $69.6K |
| Harbour Investments, Inc. | 250 | $1.58K |
| Advisory Services Network, LLC | 200 | $1.27K |